Immune checkpoint blockade to improve tumor infiltrating lymphocytes for adoptive cell therapy

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Kodumudi, Krithika N ^a   Siegel, Jessica ^a   Weber, Amy M ^a   Scott, Ellen ^a   Sarnaik, Amod A ^a   Pilon Thomas, Shari ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BTLA PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOGLOBULIN; LAG 3 PROTEIN; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; CD274 PROTEIN, MOUSE; PROGRAMMED DEATH 1 LIGAND 1;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL INFILTRATION; CELL ISOLATION; CELL MEDIATED CYTOTOXICITY; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNE CHECKPOINT BLOCKADE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; IMMUNOLOGY; NEOPLASMS, EXPERIMENTAL;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD274; FEMALE; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL;

EID: 84962861436     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153053     Document Type: Article

References (33)

1. Wu X, Zhang H, Xing Q, Cui J, Li J, Li Y, et al. PD-1 (+) CD8 (+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer 111:1391-1399. doi: 10. 1038/bjc.2014.416 PMID: 25093496
2. Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, et al. (2009) T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 16:2524-2530. doi: 10.1245/s10434-009-0585-3 PMID: 19568816
3. Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35:615-620. PMID: 22996367
4. Turcotte S, Gros A, Hogan K, Tran E, Hinrichs CS, Wunderlich JR, et al. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol 191:2217-2225. doi: 10.4049/jimmunol.1300538 PMID: 23904171
5. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239. doi: 10.1200/JCO.2008.16.5449 PMID: 18809613
6. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332-342. PMID: 12843795
7. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoSOne 6:e19499. doi: 10.1371/journal.pone.0019499 PMID: 21559358
8. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8 (+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124:2246-2259. doi: 10.1172/JCI73639 PMID: 24667641
9. Mocellin S, Nitti D CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochim Biophys Acta 1836:187-196.
10. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, et al. (2003) BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4:670-679. PMID: 12796776
11. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72:917-927. doi: 10.1158/0008-5472. CAN-11-1620 PMID: 22186141
12. Weber J, Hamid O, Amin A, O'Day S, Masson E, Goldberg SM, et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun 13:7. PMID: 23833564
13. Triebel F (2003) LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 24:619-622. PMID: 14644131
14. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. (2004) Role of LAG-3 in regulatory Tcells. Immunity 21:503-513. PMID: 15485628
15. Camisaschi C, De Filippo A, Beretta V, Vergani B, Villa A, Vergani E, et al. Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J Invest Dermatol 134:1893-1902. doi: 10.1038/jid.2014.29 PMID: 24441096
16. Demeure CE, Wolfers J, Martin-Garcia N, Gaulard P, Triebel F (2001) T Lymphocytes infiltrating various tumourtypes express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts. Eur J Cancer 37:1709-1718. PMID: 11527700
17. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. (2007) LAG-3 regulates CD8+Tcell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 117:3383-3392. PMID: 17932562
18. Serriari NE, Gondois-Rey F, Guillaume Y, Remmerswaal EB, Pastor S, Messal N, et al. (2010) BandT lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J Immunol 185:3140-3148. doi: 10.4049/jimmunol.0902487 PMID: 20693422
19. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454. doi: 10.1056/NEJMoa1200690 PMID: 22658127
20. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19:462-468. doi: 10.1158/1078-0432. CCR-12-2625 PMID: 23169436
21. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465. doi: 10.1056/NEJMoa1200694 PMID: 22658128
22. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of singleagent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175. doi: 10.1200/JCO.2009.26. 7609 PMID: 20516446
23. Pilon-Thomas S, Mackay A, Vohra N, Mule JJ Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 184:3442-3449. doi: 10.4049/jimmunol.0904114 PMID: 20194714
24. Maier H, Isogawa M, Freeman GJ, Chisari FV (2007) PD-1PD-L1 interactions contribute to the functional suppression of virus-specific CD8+T lymphocytes in the liver. J Immunol 178:2714-2720. PMID: 17312113
25. Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancerthrough CTL dysfunction. Clin Cancer Res 19:1363-1374. doi: 10.1158/1078-0432. CCR-12-2199 PMID: 23340297
26. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:2187-2194. doi: 10.1084/jem.20100643 PMID: 20819927
27. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 16:6019-6028. doi: 10.1158/1078-0432. CCR-10-1966 PMID: 20924130
28. Kocak E, Lute K, Chang X, May KF Jr., Exten KR, Zhang H, et al. (2006) Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 66:7276-7284. PMID: 16849577
29. Son CH, Bae JH, Shin DY, Lee HR, Choi YJ, Jo WS, et al. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model. J Immunother 37:1-7. PMID: 24316550
30. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73:3591-3603. doi: 10.1158/0008-5472. CAN-12-4100 PMID: 23633484
31. Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, et al. LAG-3 expression defines a subset of CD4 (+) CD25 (high) Foxp3 (+) regulatory T cells that are expanded at tumor sites. J Immunol 184:6545-6551. doi: 10.4049/jimmunol.0903879 PMID: 20421648
32. Chacon JA, Pilon-Thomas S, Sarnaik AA, Radvanyi LG Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology 2:e25581. PMID: 24319633
33. Turcotte S, Gros A, Tran E, Lee CC, Wunderlich JR, Robbins PF, et al. Tumor-reactive CD8+T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res 20:331-343. doi: 10. 1158/1078-0432. CCR-13-1736 PMID: 24218514